Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Clinical trial NCT04152499 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04152499
Sponsor: Klus Pharma Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Epithelial Ovarian Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Urothelial Carcinoma Non-Small Cell Lung Cancer Small-Cell Lung Cancer Endometrial Carcinoma Head and Neck Squamous Cell Carcinoma Breast Cancer Cervical Cancer

Start date: 2020-02-28
Primary completion: 2026-12-31
Enrollment: 1410

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.